Finance

Lists
Why is 4142 down 6.62%?
Dive Deeper
4142:TPE
Adimmune Corp
NT$14.80
-6.62%
(-1.05) 1D
Nov 20, 1:30:09 PM GMT+8  ·   TWD
All symbols
SymbolPriceChange% Change
Generating top insights for 4142...
Open
NT$15.75
High
NT$15.75
Low
NT$14.80
Mkt. cap
6.36B
Avg. vol.
1.13M
Volume
1.62M
P/E ratio
85.76
52-wk high
NT$21.50
52-wk low
NT$14.80
EPS
NT$0.17
Shares outstanding
235.29M
No. of employees
564
Open
NT$15.75
High
NT$15.75
Low
NT$14.80
Mkt. cap
6.36B
Avg. vol.
1.13M
Volume
1.62M
P/E ratio
85.76
52-wk high
NT$21.50
52-wk low
NT$14.80
EPS
NT$0.17
Shares outstanding
235.29M
No. of employees
564
News stories
From web sources and news partners
Profile
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets. Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026. Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations. In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease. In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022. In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
About Adimmune Corp
CEO-
Employees564
Founded1965
Headquarters-
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in TWD
Loading Previous Earnings...
Revenue
Net income
All values in TWD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
745.46M
82.32M
66.76M
715.67M
Cost of goods sold
376.00M
156.87M
129.59M
413.47M
Cost of revenue
376.00M
156.87M
129.59M
413.47M
Research and development expenses
74.68M
45.44M
30.55M
27.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
94.80M
79.22M
79.34M
84.37M
Operating expense
197.18M
124.66M
109.88M
112.33M
Total operating expenses
573.18M
281.54M
239.47M
525.80M
Operating income
172.28M
-199.22M
-172.71M
189.87M
Other non operating income
10.40M
710.00K
2.18M
2.03M
EBT including unusual items
200.77M
-200.47M
-172.95M
185.53M
EBT excluding unusual items
200.30M
-198.95M
-172.95M
185.53M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
220.42M
-185.54M
-160.23M
198.10M
Net profit margin
29.57%
-225.41%
-240.02%
27.68%
Earnings per share
-
-
-
0.47
Interest and investment income
9.92M
3.10M
6.47M
3.04M
Interest expense
-10.40M
-7.40M
-6.95M
-9.42M
Net interest expenses
-475.00K
-4.30M
-480.00K
-6.38M
Depreciation and amortization charges
-
-
-
-
EBITDA
219.90M
-156.74M
-128.36M
266.40M
Gain or loss from assets sale
-3.00K
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps